• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Recurrent Malignant Glioma - Pipeline Review, H2 2012 Product Image

Recurrent Malignant Glioma - Pipeline Review, H2 2012

  • ID: 2216805
  • July 2012
  • 81 pages
  • Global Markets Direct

Recurrent Malignant Glioma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Recurrent Malignant Glioma - Pipeline Review, H2 2012', provides an overview of the Recurrent Malignant Glioma therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Malignant Glioma. 'Recurrent Malignant Glioma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Recurrent Malignant Glioma.
- A review of the Recurrent Malignant Glioma READ MORE >

2
List of Tables 6
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Recurrent Malignant Glioma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Recurrent Malignant Glioma 9
Recurrent Malignant Glioma Therapeutics under Development by Companies 11
Recurrent Malignant Glioma Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Recurrent Malignant Glioma Therapeutics – Products under Development by Companies 16
Recurrent Malignant Glioma Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Recurrent Malignant Glioma Therapeutics Development 18
Boehringer Ingelheim GmbH 18
Eli Lilly and Company 19
Genentech, Inc. 20
Merck & Co., Inc. 21
Oncolytics Biotech Inc. 22
BioNumerik Pharmaceuticals, Inc. 23
Stemline Therapeutics, Inc. 24
Recurrent Malignant Glioma – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
Ridaforolimus - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Reolysin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Perifosine + Temsirolimus - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Arsenic Trioxide + Temozolomide + Radiation Therapy - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SU011248 + Irinotecan - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Enzastaurin + Bevacizumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
sarCNU - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Afatinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Avastin + Bortezomib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Avastin + Temozolomide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Carboxyamidotriazole Orotate + Temodar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Karenitecin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Zactima + Gleevec + Hydroxyurea - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 51
Bevacizumab + CPT-11 + Carboplatin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BIBW 2992 + Temozolomide - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Zactima + Etoposide - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
DTI-015 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DELTA-24-RGD-4C - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Bevacizumab + Irinotecan - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Bevacizumab + Radiation Therapy - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Dendritic Vaccine Pulsed With Multiple Peptides - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Taxol - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Thymidine + Carboplatin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Erlotinib Hydrochloride + Isotretinoin - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Bortezomib + Temozolomide - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Temozolomide + Vorinostat - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
SL-701 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Recurrent Malignant Glioma Therapeutics – Drug Profile Updates 70
Recurrent Malignant Glioma Therapeutics – Discontinued Products 78
Recurrent Malignant Glioma Therapeutics - Dormant Products 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Tables
Number of Products Under Development for Recurrent Malignant Glioma, H2 2012 9
Products under Development for Recurrent Malignant Glioma – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Boehringer Ingelheim GmbH, H2 2012 18
Eli Lilly and Company, H2 2012 19
Genentech, Inc., H2 2012 20
Merck & Co., Inc., H2 2012 21
Oncolytics Biotech Inc., H2 2012 22
BioNumerik Pharmaceuticals, Inc., H2 2012 23
Stemline Therapeutics, Inc., H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 30
Recurrent Malignant Glioma Therapeutics – Drug Profile Updates 70
Recurrent Malignant Glioma Therapeutics – Discontinued Products 78
Recurrent Malignant Glioma Therapeutics – Dormant Products 79

List of Figures
Number of Products under Development for Recurrent Malignant Glioma, H2 2012 9
Products under Development for Recurrent Malignant Glioma – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Route of Administration, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Molecule Type, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 30

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos